DK3090748T3 - Sammensætninger, der omfatter nukleotid- og oligonukleotid-prodrugs - Google Patents

Sammensætninger, der omfatter nukleotid- og oligonukleotid-prodrugs Download PDF

Info

Publication number
DK3090748T3
DK3090748T3 DK16158945.2T DK16158945T DK3090748T3 DK 3090748 T3 DK3090748 T3 DK 3090748T3 DK 16158945 T DK16158945 T DK 16158945T DK 3090748 T3 DK3090748 T3 DK 3090748T3
Authority
DK
Denmark
Prior art keywords
nukleotid
oligonukleotid
products
compositions concerning
concerning
Prior art date
Application number
DK16158945.2T
Other languages
English (en)
Inventor
Radhakrishnan P Iyer
Seetharamaiyer Padmanabhan
Original Assignee
Spring Bank Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Spring Bank Pharmaceuticals Inc filed Critical Spring Bank Pharmaceuticals Inc
Application granted granted Critical
Publication of DK3090748T3 publication Critical patent/DK3090748T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J17/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, having an oxygen-containing hetero ring not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
DK16158945.2T 2005-12-13 2006-12-13 Sammensætninger, der omfatter nukleotid- og oligonukleotid-prodrugs DK3090748T3 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US75003605P 2005-12-13 2005-12-13
US80029406P 2006-05-15 2006-05-15
US11/637,520 US8076303B2 (en) 2005-12-13 2006-12-12 Nucleotide and oligonucleotide prodrugs
EP06848625.7A EP1968612B1 (en) 2005-12-13 2006-12-13 Dinucleotide prodrugs

Publications (1)

Publication Number Publication Date
DK3090748T3 true DK3090748T3 (da) 2019-05-27

Family

ID=38194676

Family Applications (2)

Application Number Title Priority Date Filing Date
DK16158945.2T DK3090748T3 (da) 2005-12-13 2006-12-13 Sammensætninger, der omfatter nukleotid- og oligonukleotid-prodrugs
DK06848625.7T DK1968612T3 (da) 2005-12-13 2006-12-13 Dinucleotid-prodrugs

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK06848625.7T DK1968612T3 (da) 2005-12-13 2006-12-13 Dinucleotid-prodrugs

Country Status (17)

Country Link
US (6) US8076303B2 (da)
EP (3) EP1968612B1 (da)
JP (1) JP5044854B2 (da)
KR (2) KR101248873B1 (da)
CN (2) CN102796155B (da)
CY (2) CY1117576T1 (da)
DK (2) DK3090748T3 (da)
ES (2) ES2729657T3 (da)
HR (1) HRP20160531T1 (da)
HU (2) HUE044034T2 (da)
IN (1) IN2015DN01786A (da)
LT (1) LT3090748T (da)
PL (2) PL3090748T3 (da)
PT (1) PT3090748T (da)
RS (1) RS54867B1 (da)
SI (2) SI1968612T1 (da)
WO (1) WO2007070598A2 (da)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7589075B2 (en) * 2001-01-16 2009-09-15 Can-Fite Biopharma Ltd. Use of an adenosine A3 receptor agonist for inhibition of viral replication
US8076303B2 (en) * 2005-12-13 2011-12-13 Spring Bank Pharmaceuticals, Inc. Nucleotide and oligonucleotide prodrugs
CN103816174B (zh) 2008-04-03 2017-12-05 春堤制药公司 用于治疗病毒感染的化合物和方法
EP3067359A1 (en) * 2008-09-23 2016-09-14 Scott G. Petersen Self delivering bio-labile phosphate protected pro-oligos for oligonucleotide based therapeutics and mediating rna interference
CA2744987C (en) 2008-12-02 2018-01-16 Chiralgen, Ltd. Method for the synthesis of phosphorus atom modified nucleic acids
JP2012513450A (ja) * 2008-12-23 2012-06-14 ギリンダス・アメリカ・インコーポレイテッド 硫化剤およびオリゴヌクレオチドを合成するためのその使用
AU2010270714B2 (en) * 2009-07-06 2015-08-13 Wave Life Sciences Ltd. Novel nucleic acid prodrugs and methods use thereof
AU2015255202B2 (en) * 2009-07-06 2017-07-27 Wave Life Sciences Ltd. Novel nucleic acid prodrugs and methods of use thereof
CN101659612B (zh) * 2009-09-24 2013-01-09 华润赛科药业有限责任公司 一种选择性酯化的方法
CN107973833A (zh) * 2010-08-30 2018-05-01 斯普林银行医药公司 作为治疗剂的寡核苷酸类似物的设计
EP2620428B1 (en) 2010-09-24 2019-05-22 Wave Life Sciences Ltd. Asymmetric auxiliary group
SG10201700554VA (en) 2011-07-19 2017-03-30 Wave Life Sciences Pte Ltd Methods for the synthesis of functionalized nucleic acids
KR101327026B1 (ko) 2011-11-29 2013-11-13 현대자동차주식회사 운전자 보호장치
BR112015000723A2 (pt) 2012-07-13 2017-06-27 Shin Nippon Biomedical Laboratories Ltd adjuvante de ácido nucléico quiral
WO2014012081A2 (en) * 2012-07-13 2014-01-16 Ontorii, Inc. Chiral control
SG11201500239VA (en) 2012-07-13 2015-03-30 Wave Life Sciences Japan Asymmetric auxiliary group
WO2014127378A2 (en) * 2013-02-18 2014-08-21 Spring Bank Pharmaceuticals, Inc. Design of short oligonucleotides as vaccine adjuvants and therapeutic agents
EP3095461A4 (en) 2014-01-15 2017-08-23 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant having immunity induction activity, and immunity induction activator
US10149905B2 (en) 2014-01-15 2018-12-11 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant having antitumor effect and antitumor agent
JPWO2015108046A1 (ja) 2014-01-15 2017-03-23 株式会社新日本科学 抗アレルギー作用を有するキラル核酸アジュバンド及び抗アレルギー剤
MX2016009290A (es) 2014-01-16 2017-02-28 Wave Life Sciences Ltd Diseño quiral.
GB201403697D0 (en) * 2014-03-03 2014-04-16 Link Technologies Ltd Compounds and methods of use
CN106794188B (zh) * 2014-09-28 2022-12-02 华辉安健（北京）生物科技有限公司 聚合胆汁酸衍生物抑制乙型肝炎病毒和丁型肝炎病毒和ntcp运输
TW201642872A (zh) * 2015-04-07 2016-12-16 春季銀行製藥公司 用於治療ｈｃｖ感染之組成物和方法
CA2991156A1 (en) * 2015-07-02 2017-01-05 Spring Bank Pharmaceuticals, Inc. Compositions and methods for the treatment of viral infection
EP3426671A4 (en) * 2016-03-11 2019-11-20 Spring Bank Pharmaceuticals, Inc. COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF INFECTIONS
SG11201900154VA (en) * 2016-07-15 2019-02-27 Sperovie Biosciences Inc Compounds, compositions, and methods for the treatment of disease
JOP20170192A1 (ar) * 2016-12-01 2019-01-30 Takeda Pharmaceuticals Co داي نوكليوتيد حلقي
US20200055883A1 (en) 2017-02-17 2020-02-20 Eisai R&D Management Co., Ltd. Cyclic di-nucleotides derivative for the treatment of cancer
AR113224A1 (es) 2017-04-28 2020-02-19 Novartis Ag Conjugados de anticuerpo que comprenden un agonista de sting
US11584774B2 (en) 2017-09-11 2023-02-21 F-star Therapeutics, Inc. Compounds, compositions, and methods for the treatment of disease
WO2019051489A1 (en) * 2017-09-11 2019-03-14 Sperovie Biosciences, Inc. COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING DISEASE
CN110467647B (zh) * 2018-05-09 2022-08-30 博瑞生物医药（苏州）股份有限公司 双核苷酸前体药物的制备方法
CN110467646A (zh) * 2018-05-09 2019-11-19 博瑞生物医药（苏州）股份有限公司 双核苷酸前体药物
CN111918870B (zh) * 2018-05-18 2022-07-08 正大天晴药业集团股份有限公司 氘代的低聚核苷酸及前体药物
AU2019277679A1 (en) 2018-06-01 2020-12-24 Eisai R&D Management Co., Ltd. Methods for the treatment of bladder cancer
FR3082434B1 (fr) 2018-06-14 2021-04-30 Cairdac Implant cardiaque autonome de type "capsule leadless", comprenant un recuperateur d'energie a lame piezoelectrique
WO2020036199A1 (en) 2018-08-16 2020-02-20 Eisai R&D Management Co., Ltd. Salts of compounds and crystals thereof
US20210170043A1 (en) 2018-10-31 2021-06-10 Novartis Ag Dc-sign antibody conjugates comprising sting agonists
WO2020089815A1 (en) 2018-10-31 2020-05-07 Novartis Ag Antibody conjugates comprising sting agonist
WO2020114495A1 (zh) * 2018-12-06 2020-06-11 正大天晴药业集团股份有限公司 二核苷酸化合物及其前体药物
CN111484541B (zh) * 2019-01-25 2023-06-02 博瑞生物医药（苏州）股份有限公司 双核苷酸前体药物及其制备方法
CN111484540B (zh) * 2019-01-25 2023-09-08 博瑞生物医药（苏州）股份有限公司 含双核苷酸结构的化合物
JP7421280B2 (ja) 2019-07-30 2024-01-24 三和シヤッター工業株式会社 建具

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US688183A (en) 1900-12-17 1901-12-03 Carl C Lantz Adjusting-clip for garment-supporters.
DE2817041C2 (de) 1978-04-19 1987-02-19 Reich Spezialmaschinen GmbH, 7440 Nürtingen Vorrichtung zum Aufteilen von Platten
CS264222B1 (en) * 1986-07-18 1989-06-13 Holy Antonin N-phosphonylmethoxyalkylderivatives of bases of pytimidine and purine and method of use them
US5204466A (en) 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds
US5914331A (en) 1990-02-01 1999-06-22 Emory University Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane
JPH05506033A (ja) 1990-04-18 1993-09-02 ノーウィッチ、イートン、ファーマスーティカルズ、インコーポレーテッド 抗微生物性キノロニルラクタム類
US5444063A (en) 1990-12-05 1995-08-22 Emory University Enantiomerically pure β-D-dioxolane nucleosides with selective anti-Hepatitis B virus activity
US5432165A (en) 1992-04-06 1995-07-11 Oclassen Pharmaceuticals, Inc. Methods for the treatment of infection caused by Hepatitis B virus (HBV)
US5955591A (en) * 1993-05-12 1999-09-21 Imbach; Jean-Louis Phosphotriester oligonucleotides, amidites and method of preparation
FR2705099B1 (fr) 1993-05-12 1995-08-04 Centre Nat Rech Scient Oligonucléotides phosphorothioates triesters et procédé de préparation.
FR2709754B1 (fr) 1993-09-10 1995-12-01 Centre Nat Rech Scient Composés 2' ou 3'-déoxy- et 2', 3'-didéoxy-beta-L-pentofuranonucléosides, procédé de préparation et application thérapeutique, notamment anti-virale.
US5587362A (en) 1994-01-28 1996-12-24 Univ. Of Ga Research Foundation L-nucleosides
US5581639A (en) 1995-05-04 1996-12-03 National Research Council Of Canada Raman-nath diffraction grating
AU4156197A (en) 1996-08-21 1998-03-06 Hybridon, Inc. Oligonucleotide prodrugs
WO1998017281A1 (en) 1996-10-24 1998-04-30 Vion Pharmaceuticals, Inc. MONOPHOSPHATE PRODRUGS OF β-L-FD4C AND β-L-FddC AS POTENT ANTIVIRAL AGENTS
US6444652B1 (en) 1998-08-10 2002-09-03 Novirio Pharmaceuticals Limited β-L-2'-deoxy-nucleosides for the treatment of hepatitis B
CA2599597A1 (en) 1998-08-10 2000-02-24 Idenix (Cayman) Limited .beta.-l-2'-deoxy-nucleosides for the treatment of hepatitis b
MXPA01001507A (es) 1998-08-10 2003-09-10 Novirio Pharmaceuticals Ltd °l-2'desoxi-nucleosidos para el tratamiento de hepatitis b.
US6875751B2 (en) 2000-06-15 2005-04-05 Idenix Pharmaceuticals, Inc. 3′-prodrugs of 2′-deoxy-β-L-nucleosides
AU2001282941C1 (en) 2000-07-21 2016-12-22 Gilead Sciences, Inc. Prodrugs of phosphonate nucleotide analogues and methods for selecting and making same
KR20040074594A (ko) * 2001-05-16 2004-08-25 마이크로로직스 바이오테크, 인코포레이티드 핵산을 기본으로 하는 화합물 및 이의 사용방법
US8076303B2 (en) * 2005-12-13 2011-12-13 Spring Bank Pharmaceuticals, Inc. Nucleotide and oligonucleotide prodrugs
CN101146337B (zh) 2006-09-15 2011-04-20 华为技术有限公司 新接入节点随机接入的方法及其系统
CN103816174B (zh) * 2008-04-03 2017-12-05 春堤制药公司 用于治疗病毒感染的化合物和方法

Also Published As

Publication number Publication date
EP3090748B1 (en) 2019-02-20
US10047114B2 (en) 2018-08-14
ES2573928T3 (es) 2016-06-13
US20070149462A1 (en) 2007-06-28
KR101123534B1 (ko) 2012-03-13
HRP20160531T1 (hr) 2016-08-12
EP1968612A4 (en) 2013-01-09
EP3090748A1 (en) 2016-11-09
CY1117576T1 (el) 2017-04-26
WO2007070598A2 (en) 2007-06-21
ES2729657T3 (es) 2019-11-05
US20200087338A1 (en) 2020-03-19
CY1121639T1 (el) 2020-07-31
PL3090748T3 (pl) 2020-03-31
EP1968612B1 (en) 2016-03-09
US20180273574A1 (en) 2018-09-27
WO2007070598A9 (en) 2007-11-08
WO2007070598A3 (en) 2008-10-30
US8076303B2 (en) 2011-12-13
SI1968612T1 (sl) 2016-10-28
HUE029190T2 (en) 2017-02-28
DK1968612T3 (da) 2017-05-22
JP2009519345A (ja) 2009-05-14
RS54867B1 (sr) 2016-10-31
IN2015DN01786A (da) 2015-07-10
SI3090748T1 (sl) 2019-09-30
PT3090748T (pt) 2019-06-04
KR20080072084A (ko) 2008-08-05
PL1968612T3 (pl) 2016-11-30
JP5044854B2 (ja) 2012-10-10
WO2007070598A8 (en) 2008-12-31
KR20110125677A (ko) 2011-11-21
US10344046B2 (en) 2019-07-09
LT3090748T (lt) 2019-08-26
CN101437397A (zh) 2009-05-20
EP3553072A1 (en) 2019-10-16
HUE044034T2 (hu) 2019-09-30
US8691787B2 (en) 2014-04-08
US20120264709A1 (en) 2012-10-18
US20140323554A1 (en) 2014-10-30
US20160060287A1 (en) 2016-03-03
EP1968612A2 (en) 2008-09-17
CN102796155B (zh) 2015-08-26
KR101248873B1 (ko) 2013-04-02
CN101437397B (zh) 2012-09-05
CN102796155A (zh) 2012-11-28

Similar Documents

Publication Publication Date Title
DK3090748T3 (da) Sammensætninger, der omfatter nukleotid- og oligonukleotid-prodrugs
ITMI20050728A1 (it) Formulazione innovativa
NO20055686D0 (no) Sammensetning
RU2398586C3 (ru) Фармацевтическая композиция
DE602006014147D1 (de) Aroma- und duftstoffzusammensetzung
ITMI20041252A1 (it) Composizioni perfluoroelastomeriche
DK3348624T3 (da) Sammensætninger, der omfatter hfc-1234yf
DE602006020277D1 (de) Warenverpackung
DE602006015807D1 (de) Abgeschwächter dengue-serotyp-2-stamm
ATE555657T1 (de) Fungizidzusammensetzungen
DK1741339T3 (da) Pesticid sammensætning
DE602005016978D1 (de) Quecksilberfreisetzende Zusammensetzungen
DE502006006590D1 (de) Biozide zusammensetzungen
IL207372A0 (en) Phenylpyrrole derivatives, compositions comprising the same and uses thereof
BRPI0618332A2 (pt) embalagem
FR2883132B1 (fr) Composition alimentaire suppletive
FR2905563B1 (fr) Composition alimentaire.
FR2892275B1 (fr) Poudrier.
DE502006001779D1 (de) Allylorganopolysiloxane aufweisende vernetzbare zusammensetzungen
FR2882894B1 (fr) Composition alimentaire suppletive
FR2885520B1 (fr) Composition cosmetique
BRPI0614413A2 (pt) composto, e, composição farmacêutica
DE502006007368D1 (de) Fördervorrichtung
FR2885521B1 (fr) Composition cosmetique
BRPI0614412A2 (pt) composto, e, composição farmacêutica